Entrepreneurial pathways to impact: spinning-out your research with Nobel Laureate Sir Greg Winter as headline speaker
Hosted by Cambridge Innovation Capital and Cambridge Enterprise
18 October 2022, 15.30 – 17.30 plus networking
Join us for talks, case studies and advice to inspire academics and researchers in their journey to create commercial impact from research through the formation of spin-out companies.
Highlights of the event include:
Headline speaker Sir Greg Winter
Sir Greg Winter is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies, credited with having invented techniques to both humanise (1986) and, later, to fully humanise using phage display, antibodies for therapeutic uses. Sir Greg has established hugely successful spin out companies including Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics.
Founder stories from award winning spin-out companies Cambridge GaN Devices, Pharmenable and Nu Quantum
Professor Florin Udrea is a professor in semiconductor engineering and head of the High Voltage Microelectronics and Sensors Laboratory at University of Cambridge. He has founded five companies including Cambridge Semiconductor, Cambridge CMOS Sensors, Cambridge Microelectronics, Flusso and Cambridge GaN Devices (CGD). CGD is a fabless semiconductor company that develops energy-efficient GaN-based power devices to make greener electronics possible. It completed its $9.5M Series A fundraising in March 2021. In autumn 2021, the company was named Tech Scaleup of the Year by Business Weekly in the category of green electronics and was awarded the UK Business Angels Association (UKBAA) DeepTech Investment of the Year.
Dr Hannah Sore, a medicinal chemist by training, is recognised for championing innovative methods for discovering much needed new drugs. She brings over 20 years of research expertise within the life sciences and drug discovery sector at Millennium Pharmaceuticals, Astex Therapeutics and at the University of Cambridge. Hannah is the co-founder and CEO of Pharmenable, an AI drug discovery company unlocking challenging targets by mapping unexplored chemical space to deliver innovative medicines. Pharmenable was recently awarded the PLG Collaboration Deal of the Year Award.
Carmen Palacios-Berraquero, Cofounder & CEO, is an award-winning Quantum physicist and inventor, listed in Forbes magazine as a ‘Founders Forum Rising Star 2021’. In 2018, Carmen was awarded the Jocelyn Bell Burnell Medal and Prize for her work on 2D materials and Quantum optics, and for discovering and patenting the unique single-photon source technology which has since been commercialised by Nu Quantum, a company creating high-performance, quantum networking solutions that will predicate the future of quantum information processing.